Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 4/20 | 0.37 |
| ▸ | TYK2 | P29597 | 8/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21090989 | 0.83 | HCRTR1 (0.43) | HCRTR1HCRTR2JAK2TYK2 | |
| SCHEMBL15698670 | 0.79 | JAK2 (0.46) | JAK2TYK2 | |
| SCHEMBL28968048 | 0.77 | GABRA1 (0.61) | GABRA1GABRB2PTPN5ANPEPDPP4 | |
| SCHEMBL30117290 | 0.77 | GABRA1 (0.61) | GABRA1GABRB2PTPN5ANPEPDPP4 | |
| SCHEMBL24359763 | 0.75 | GABRA1 (0.50) | GABRA1GABRB2PTPN5ANPEPDPP4 | |
| SCHEMBL16527783 | 0.74 | GABRA1 (0.76) | GABRA1GABRB2PTPN5ANPEPDPP4 | |
| SCHEMBL23863627 | 0.69 | HCRTR1 (0.39) | HCRTR1HCRTR2JAK2TYK2 | |
| SCHEMBL31280994 | 0.68 | HCRTR1 (0.41) | HCRTR1HCRTR2JAK2TYK2 | |
| SCHEMBL31280858 | 0.68 | TYK2 (0.40) | HCRTR1HCRTR2JAK2TYK2 | |
| SCHEMBL199730 | 0.68 | GABRA1 (1.00) | GABRA1GABRB2PTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495358-B1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2022-04-27 | — | — | EP | disclosed |